Skip to content

Addiction: all studies

Page 330 of 857: studies 3,291 to 3,300 of 8,563, newest first. Back to the addiction overview

Research

Is the antidepressant effect of ketamine separate from its psychotomimetic effect? A review of rodent models.

Neuropharmacology November 1, 2024 M C Acero-Castillo, M B M Correia, F V Caixeta et al. 7 citations

Ketamine is an NMDA (N-methyl-d-aspartate) glutamate receptor antagonist, which has a myriad of dose-dependent pharmacological and behavioral effects, including anesthetic, sedative, amnestic, analgesic, and anti-inflammatory properties. Intriguingly, ketamine at subanesthetic doses displays a relevant profile both in mimicking symptoms of schizophrenia and also as the first fast-acting...

Intraoperative Pain Management for Treatment-Resistant Complex Regional Pain Syndrome: A Case Report.

Cureus November 1, 2024 Catherine R La Spina, Patricia Pozo, Gisele J Wakim

Complex regional pain syndrome (CRPS) is a chronic neuropathic pain disorder often following trauma, associated with severe pain and autonomic disturbances in the affected limbs. Managing CRPS is challenging due to the lack of FDA-approved medications, often requiring off-label treatments. Traditional options like nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids show limited...

DOI: 10.7759/cureus.72935 (opens in new tab) Full text (opens in new tab) Chronic neuropathic pain Crps pathophysiology Intraoperative ketamine Stages of crps +5

Optimized psilocybin production in tryptophan catabolism‐repressed fungi

Microbial Biotechnology November 1, 2024 Slavica Janevska, Sophie Weiser, Ying Huang et al. 13 citations

Abstract The high therapeutic potential of psilocybin, a prodrug of the psychotropic psilocin, holds great promise for the treatment of mental disorders such as therapy‐refractory depression, alcohol use disorder and anorexia nervosa. Psilocybin has been designated a ‘Breakthrough Therapy’ by the US Food and Drug Administration, and therefore a sustainable production process must be established...

DOI: 10.1111/1751-7915.70039 (opens in new tab) Psilocybin Tryptamine Aspergillus nidulans Biochemistry +1

Exploring mindfulness interventions across cultures: a comparative meta-analysis of mindfulness interventions for athletes in Western and Eastern contexts

Frontiers in Psychology October 31, 2024 Shizheng Du, Ziheng Ning 18 citations

Objective Applying mindfulness training across cultures can be challenging because its internal motivation depends on values, but there are differences between Western and Eastern contexts. This meta-analysis examines the comparative impacts of the Western Mindfulness-Acceptance-Commitment (MAC) approach and the culturally-adapted Chinese Mindfulness-Acceptance-Insight-Commitment (MAIC)...

Effects of mindfulness intervention on competition state anxiety in sprinters—a randomized controlled trial

Frontiers in Psychology October 31, 2024 Maggie Yu, Guang Bo Dou, Chen Gong 8 citations

Objectives With the rapid growth of China’s sprint program’s international competitiveness, the psychological problems of sprinters have become a common concern in sports training theory and practice. Hence, the study examined the impact of a 7-week Mindfulness training program on competition state anxiety in Chinese sprinters. Methods Twenty-four sprinters (M age = 22.46 ± 1.351) were selected...

DOI: 10.3389/fpsyg.2024.1418094 (opens in new tab) Mindfulness Anxiety Randomized controlled trial Intervention counseling +5

Exploration of attitudes towards the mystical experience in the context of psychedelic assisted psychotherapy amongst psychiatry trainees based in the West of Scotland

Consciousness, Spirituality & Transpersonal Psychology October 31, 2024 Cassie Maguire

Modern clinical trials suggest early evidence for the safety and efficacy of psychedelic assisted psychotherapy (PAP) in domains including addictions, dysphoria related to life-threatening illnesses and depression. Research suggests that the mystical experience (ME) under psychedelics appears to play a key role in positive outcomes. With a growing evidence base, it is possible that PAP may be...

DOI: 10.53074/cstp.2024.70 (opens in new tab) Psychedelic therapy Psychiatry training Mental health treatment Mystical experiences +1

Can jinn be a tonic? The therapeutic value of spirit-related beliefs, practices and experiences

Filosofia Unisinos October 30, 2024 Anastasia Philippa Scrutton 4 citations

Religion and spirituality are increasingly associated with mental health, yet spirit-related practices, beliefs and experiences (SPBEs) are regarded with more suspicion. This suspicion is misplaced, and worryingly so, since, I argue, it shuts down a potentially therapeutic avenue in relation to anomalous experiences such as hearing voices and sensing the presence of the dead. A presupposition...

Microdosing of alteplase leads to thrombolysis in an in vitro flow model of cardiac microvascular obstruction

European Heart Journal October 28, 2024 A Milusev, Y Roesch, P Wolint et al.

Abstract Background Cardiac microvascular obstruction (MVO) is a frequent injury of the myocardial microcirculation after successful recanalisation of the occluded coronary artery in myocardial infarction. At least in part, MVO is caused by embolised microthrombi of less than 200 µm diameter [1]. MVO leads to hypoperfusion of the myocardium and negatively affects patient outcomes. However,...

Ketamine-induced altered states of consciousness: a systematic review of implications for therapeutic outcomes in psychiatric practices.

European Archives of Psychiatry and Clinical Neuroscience October 28, 2024 Kaike Thiê da Costa Gonçalves, Vagner Deuel O de Tavares, Maria Luiza de Morais Barros et al. 5 citations

This systematic review aims to elucidate the nexus between ketamine's psychoactive properties and its efficacy in treating a broad spectrum of psychiatric disorders. We searched three databases and used citation tracking to include 29 studies. Predominantly, mood disorders, including bipolar disorder (BD) and major depressive disorder (MDD) (MDD + BD: + n = 25 studies), a large part of them...

Psilocin, the Psychoactive Metabolite of Psilocybin, Modulates Select Neuroimmune Functions of Microglial Cells in a 5-HT2 Receptor-Dependent Manner

Molecules October 28, 2024 Ishvin Riar, Andis Klegeris, Kennedy R. Wiens et al. 21 citations

Neuroinflammation that is caused by microglia, the main immune cells of the brain, contributes to neurodegenerative diseases. Psychedelics, including psilocybin and lysergic acid diethylamide (LSD), possess certain anti-inflammatory properties and, therefore, should be considered as drug candidates for treating neuroinflammatory pathologies. When ingested, psilocybin is rapidly dephosphorylated...

DOI: 10.3390/molecules29215084 (opens in new tab) Psilocybin Hallucinogen Metabolite Pharmacology +1